| Cindy L Beske, CNM | |
|
903 Medical Center Dr, Arlington, WA 98223-1697 | |
| (360) 435-0242 | |
| (360) 435-9135 |
| Full Name | Cindy L Beske |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 903 Medical Center Dr, Arlington, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710976014 | NPI | - | NPPES |
| 2089806 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | NP1307 (Alaska) | Secondary |
| 367A00000X | Advanced Practice Midwife | AP60773706 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Cindy L Beske, CNM 1400 E. Kincaid Street, Attn: Credentialing, Mount Vernon, WA 98274-4127 Ph: (360) 814-6724 | Cindy L Beske, CNM 903 Medical Center Dr, Arlington, WA 98223-1697 Ph: (360) 435-0242 |
News Archive
A Canadian-led study involving researchers from 41 countries has demonstrated in the world's largest study of acute coronary syndromes (ACS) that a new anti-thrombotic therapy is safer and as effective as the traditional therapy used in preventing heart attacks, death and ischemia in people with serious heart conditions.
Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.
A new treatment may bring hope for people who suffer from muscle cramps or spasms from neuromuscular disorders, diseases such as multiple sclerosis or simply from nighttime leg cramps that keep people from sleeping, according to a study released today that will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC, April 18 to 25, 2015.
Ultraviolet light - a culprit behind sunburns, wrinkles and skin cancer - offers benefits for some skin conditions, according to the April issue of Mayo Clinic Health Letter.
Sistemic Ltd., the recent winners of the coveted Most Promising Life Science Company by Nexxus, today announced the launch of their SistemTOX™ early predictive and investigative drug toxicity screening service. Based on world-leading Scottish microRNA research and technology, SistemTOX™ filters out potentially harmful compounds early in the development process, helping to save millions of pounds in costs.
› Verified 4 days ago
Dr. Jessica Lynette Hurwitz, DNP, CNM, ARNP Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 903 Medical Center Dr, Arlington, WA 98223 Phone: 360-435-0242 Fax: 360-435-9135 |